Abstract:
The present invention is directed to a process for making Tetracyclic Heterocycle Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2 and R3 are defined above herein. The present invention is also directed to compounds that are useful as synthetic intermediates in the process of the invention.
Abstract:
The invention features compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use.
Abstract:
Uniform web content may be provided across affiliated web sites of an organization and associated parties in a centralized, personalized, consistent, dynamic, fast-rendering manner that may be easy to maintain and easily inserted into any of the affiliated web sites. The affiliated web sites may each include code to refer to rendering logic residing on a centralized web tier for the uniform web content to be sent with unique web content to terminal devices of users. The uniform web content may load in advance of unique web content of the particular affiliated web site when displaying a corresponding web page to a user. The uniform web content may be generated on the client side and integrated with unique web content, providing for a consistent look and feel through the affiliated web sites.
Abstract:
This invention relates to specific compounds and their pharmaceutically acceptable salts of the general formula: wherein Q is —CR═CR′— and Ring A is an aryl, heteroaryl or heterocyclic ring or ring system. This invention also relates to pharmaceutical compositions comprising such specific compounds or their pharmaceutically acceptable salts and a pharmaceutically acceptable carrier or adjuvant.
Abstract:
This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
Abstract:
This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
Abstract:
This invention relates to compounds of the general formula: in which Q is an ethynyl or ethenyl moiety; Ring A is an aryl, heteroaryl or heterocyclic ring or ring system; and the remaining variable groups are as defined herein, and to their preparation and use.
Abstract:
Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-L-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and a resultant increase in apoptosis of the target cells is detected. The contacting step may be effected by administering to a pharmaceutical composition comprising a therapeutically effective amount of The compoundic mimetic, wherein the individual may be subject to concurrent or antecedent radiation or chemotherapy for treatment of a neoproliferative pathology.
Abstract:
Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-L-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and a resultant increase in apoptosis of the target cells is detected. The contacting step may be effected by administering to a pharmaceutical composition comprising a therapeutically effective amount of the dimeric mimetic, wherein the individual may be subject to concurrent or antecedent radiation or chemotherapy for treatment of a neoproliferative pathology.
Abstract:
The invention includes a method and apparatus adapted for providing quality-of-service to a packet flow within a Radio Access Network (RAN). In one embodiment, a method includes receiving packets of a packet flow at a first network element of the RAN, where the packet flow is associated with an application normally served in a best effort service class of the RAN and each packet of the packet flow comprises an indication of a quality-of-service policy to be applied to the packet flow within the RAN, and, applying the indicated quality-of-service policy to the packet flow within the RAN. The quality-of-service policy to be applied to the packet flow within the RAN is based on at least one characteristic of the packet flow, which may be determined in any manner, such as using information included in the packet headers, using deep packet inspection techniques, and the like. The indication of the quality-of-service policy to be applied to the packet flow within the RAN may be set either inside the RAN or outside the RAN.